Sign in →

Test ID RAVUM Ravulizumab Complement Blockage Monitoring, Serum

Ordering Guidance

To measure therapeutic concentrations of ravulizumab, order RAVU / Ravulizumab, Serum.

Specimen Required

Patient Preparation: Fasting preferred.

Supplies: Sarstedt 5 mL Aliquot Tube (T914)

Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Immediately after specimen collection, place the tube on wet ice.

2. Centrifuge at 4° C and aliquot serum into 5 mL plastic vial.

3. Freeze specimen within 30 minutes.

Useful For

Monitoring of complement blockage by ravulizumab


Investigation of suspected alternative pathway complement deficiency, atypical hemolytic uremic syndrome, C3 glomerulonephritis, dense-deposit disease


Ravulizumab is a new complement C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ravulizumab. Ravulizumab has 4 different amino acids from eculizumab, which allow greater affinity for the FcRn immunoglobulin receptor and change the affinity of the molecule for C5.

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

Ravulizumab Complement Blockage, S

Specimen Type

Serum Red

Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Red Frozen 14 days

Reference Values

≥46% normal

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
RAVUM Ravulizumab Complement Blockage, S 74520-8


Result ID Test Result Name Result LOINC Value
609500 Ravulizumab Complement Blockage, S 74520-8

NY State Approved


Day(s) Performed


Report Available

1 to 7 days